TABLE 2.

Patient inclusion and exclusion criteria.

Inclusion criteria

Understand the explanations related to this study and cooperate with the completion of relevant assessments. Diagnosed with malignant lung tumors and regularly undergoing anti‐tumor treatment. Signed an informed consent form. Expected survival period of more than 3 months. ECOG score of 0–1.

Exclusion criteria

Patients with other malignant tumors. Patients with weight‐bearing bone metastasis or spinal instability score (SINS) ≥5 points. Patients with deep vein thrombosis. Patients with gastrointestinal bleeding. Patients with gastric, intestinal, or bladder fistula. Various clinically significant heart rate, conduction, resting ECG morphological abnormalities, such as conduction block, frequent premature ventricular contractions, researcher‐judged clinically significant ST segment depression or elevation, etc. Severe exercise dysfunction. Severe respiratory diseases, such as interstitial lung disease, severe asthma, pulmonary embolism, etc. Patients with active and bleeding prone constitution. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 100 mmHg). Spinal cord compression. Unstable brain metastasis. Patients with active infections (T ≥ 38°C). Patients with any of the following laboratory indicator abnormalities: PLT ≤80 × 109/L, absolute neutrophil count (ANC) <1.5 × 109/L, HGB<90 g/L. Without family caregivers. Other situations judged by the researcher as unsuitable for entry into this study.